<DOC>
	<DOCNO>NCT00449254</DOCNO>
	<brief_summary>Multi-center , multiple-dose , randomize , double-blind , three-arm , placebo-controlled study fixed-dose repeated oral dose 30 day 10 mg 30 mg MP-101 placebo obese subject .</brief_summary>
	<brief_title>Phase 2a Randomized , Double-Blind Study Oleoyl-Estrone Male Morbidly Obese Adults</brief_title>
	<detailed_description />
	<mesh_term>Oleoyl-estrone</mesh_term>
	<mesh_term>Estrone</mesh_term>
	<mesh_term>Estropipate</mesh_term>
	<criteria>Subject willing able provide sign informed consent . Subject male 1860 year age . Subject obese define BMI 40 55 . Subject reasonably healthy reasonably acceptable medical history Subject stable weight past 30 day per subject report . Subject least one factor metabolic Subject exhibit stable behavior pattern regard smoke exercise Subject read , speak write English language agree follow study procedure . Subjects receive investigational medication within 3 month prior administration study drug Subjects confirm positive result UDS Alcohol Subjects unwilling return clinical research center specify day treatment period . Subjects take exclusionary medication Subjects clinically significant laboratory abnormality illness , opinion Investigator , would contraindicate study participation Subjects history test positive Hepatitis B virus , Hepatitis C virus , HIV . Subject involve formal informal ( selfimposed ) diet regimen within last 30 day . Subject confirmed diagnosis history cancer , exception nonmelanoma skin cancer . Subject otherwise unsuitable study , opinion investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>